| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1970) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | M01CC01 |
| UNII: | GNN1DV99GX |
Structure
| InChI Key | VVNCNSJFMMFHPL-VKHMYHEASA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value | |
|---|---|---|
| Molecular Formula | C5H11NO2S | |
| Molecular Weight | 149.22 | |
| AlogP | 0.11 | |
| Hydrogen Bond Acceptor | 3.0 | |
| Hydrogen Bond Donor | 3.0 | |
| Number of Rotational Bond | 2.0 | |
| Polar Surface Area | 63.32 | |
| Molecular species | ZWITTERION | |
| Aromatic Rings | 0.0 | |
| Heavy Atoms | 9.0 |
Pharmacology
| Action | Mechanism of Action | Reference | |
|---|---|---|---|
| CHELATING AGENT | Copper chelating agent | DailyMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | ||
|---|---|---|---|---|---|---|---|
|
Enzyme
Hydrolase
|
- | 50000 | - | - | - | ||
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 100 |
Metabolites
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference | ||
|---|---|---|---|---|---|
| Central Nervous System Neoplasms | 2 | D016543 | ClinicalTrials |
Related Entries
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 52-67-5 |
| ChEBI | 7959 |
| ChEMBL | CHEMBL1430 |
| DrugBank | DB00859 |
| DrugCentral | 2081 |
| EPA CompTox | DTXSID6037069 |
| FDA SRS | GNN1DV99GX |
| Guide to Pharmacology | 7264 |
| KEGG | C07418 |
| PDB | LEI |
| PharmGKB | PA450840 |
| PubChem | 5852 |
| SureChEMBL | SCHEMBL4343 |
| ZINC | ZINC000000114127 |
CONTENTS